• Molecular NameN/A
  • SynonymN/A
  • Weight467.52
  • Drugbank_IDDB00684
  • ACS_NO32986-56-4
  • Show 3D model
  • LogP (experiment)-5.8
  • LogP (predicted, AB/LogP v2.0)-8.24
  • pka6.7, 8.3, 9.9
  • LogD (pH=7, predicted)-12.5
  • Solubility (experiment)666 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)0.33
  • LogSw (predicted, AB/LogsW2.0)1028.04
  • Sw (mg/ml) (predicted, ACD/Labs)1000.0
  • No.of HBond Donors15
  • No.of HBond Acceptors14
  • No.of Rotatable Bonds6
  • TPSA268.17
  • StatusFDA approved
  • AdministrationIV, IM, inhalation, ophthalmic
  • PharmacologyAn aminoglycoside antibiotic used to treat various types of bacterial infections, particularly Gram-negative infections.
  • Absorption_value0.0
  • Absorption (description)The bioavailability of tobramycin may vary because of individual differences in nebulizer performance and airway pathology.
  • Caco_2N/A
  • Bioavailability1.0
  • Protein binding10.0
  • Volume of distribution (VD)0.3 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmFollowing parenteral administration, little, if any, metabolic transformation occurs.
  • Half life2~3 h after intravenous (IV) administration.
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=441mg/kg (s.c.)